From: 155Tb production by cyclotrons: what level of 155Gd enrichment allows clinical applications?
Target organ | 154gTb-cm09 | 155Tb-cm09 | 156gTb-cm09 | 156m1Tb-cm09 | 156m2Tb-cm09 |
---|---|---|---|---|---|
Adreanals | 1.68E-01 | 6.56E-02 | 4.69E-01 | 6.78E-03 | 1.44E-03 |
Brain | 2.61E-02 | 9.25E-03 | 5.68E-02 | 1.38E-03 | 1.22E-03 |
Esophagus | 4.93E-02 | 1.52E-02 | 1.10E-01 | 1.98E-03 | 1.24E-03 |
Eyes | 2.58E-02 | 9.09E-3 | 5.57E-02 | 1.36E-03 | 1.22E-03 |
Gallbladder wall | 7.75E-02 | 2.66E-02 | 1.97E-01 | 3.05E-03 | 1.27E-03 |
Left colon | 5.91E-02 | 2.04E-02 | 1.44E-01 | 2.50E-03 | 1.71E-03 |
Small intestine | 5.10E-02 | 1.67E-02 | 1.19E-01 | 2.11E-03 | 1.71E-03 |
Stomach wall | 5.60E-02 | 1.87E-02 | 1.29E-01 | 2.49E-03 | 2.05E-03 |
Right colon | 5.59E-02 | 1.87E-02 | 1.34E-01 | 2.31E-03 | 1.71E-03 |
Rectum | 4.13E-02 | 1.33E-02 | 9.11E-02 | 1.80E-03 | 1.70E-03 |
Heart wall | 6.75E-02 | 2.14E-02 | 1.35E-01 | 3.64E-03 | 4.98E-03 |
Kidneys | 3.92E-01 | 3.48E-01 | 1.29E00 | 4.27E-02 | 3.99E-02 |
Liver | 1.01E-01 | 5.06E-02 | 2.77E-01 | 6.10E-03 | 4.74E-03 |
Lungs | 4.78E-02 | 1.99E-02 | 1.10E-01 | 3.00E-03 | 3.36E-03 |
Pancreas | 6.14E-02 | 1.97E-02 | 1.46E-01 | 2.37E-03 | 1.22E-03 |
Prostate | 4.15E-02 | 1.23E-02 | 9.27E-02 | 1.55E-03 | 1.22E-03 |
Salivary Glands | 6.42E-02 | 4.67E-02 | 1.74E-01 | 6.57E-03 | 8.32E-03 |
Red Marrow | 4.11E-02 | 1.15E-02 | 9.39E-02 | 1.41E-03 | 1.03E-03 |
Osteogenic cells | 6.00E-02 | 8.61E-02 | 1.75E-01 | 1.78E-02 | 1.04E-02 |
Spleen | 7.72E-02 | 3.27E-02 | 2.12E-01 | 3.53E-03 | 1.75E-03 |
Testes | 2.92E-02 | 8.58E-03 | 6.09E-02 | 1.20E-03 | 1.21E-03 |
Thymus | 4.31E-02 | 1.22E-02 | 8.86E-02 | 1.75E-03 | 1.24E-03 |
Thyroid | 3.55E-02 | 1.10E-02 | 7.60E-02 | 1.54E-03 | 1.22E-03 |
Urinary bladder wall | 3.82E-02 | 1.12E-02 | 8.24E-02 | 1.48E-03 | 1.22E-03 |
Total body | 3.57E-02 | 1.36E-02 | 8.13E-02 | 1.91E-03 | 1.74E-03 |
Effective dose | 4.44E-02 | 1.86E-02 | 1.09E-01 | 2.47E-03 | 2.06E-03 |